Sunday, December 19, 2004

From the Canadian Press:
Celebrex a heart risk: Health Canada
Health Canada has pulled authorization of pain relief drug Celebrex for the treatment of a rare genetic disease, following "new information" linking the drug to an increased risk of heart attack.

The department has withdrawn authorization for Pfizer Inc., to market the drug for the treatment of Familial Adenomatous Polyposys, a disease "highly predictive" of colorectal cancer, spokesman Ryan Baker said late Friday.

No comments: